Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Adjuvant NSCLC (LungMate-008)
NCT04772287Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04772287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772287.